The effectiveness of PET-scan in diagnosis and treatment of non-small cell lung carcinoma (NSCLC) and lymphoma: A comprehensive review of literature

Journal of Isfahan Medical School

Volumn 29, Issue 167, 2012, Pages

  Ravaghi, Hamid ^a   Sari, Ali Akbari ^a   Sarvari, Sima ^b   Mobinizadeh, Mohammad Reza ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHANTOU UNIVERSITY   (China)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Imaging; Lymphoma; NSCLC; PET scan

Indexed keywords

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; LYMPHOMA; MEDIASTINOSCOPY; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; SAFETY; SENSITIVITY AND SPECIFICITY;

EID: 84857492402     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care 2007; 23(1): 30-5.
2. Department of Health. A framework for the development of Positron Emission Tomography (PET) services in England [Online] 2005. Available from: URL: http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4121030.pdf.
3. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007; 11(44): 3-267.
4. Abbasidezfuli A, Adhami Sh, Javaherzadeh M, Daneshvar A, Pejhan S, Arab M, et al. Role of operation in lung cancer. Journal of Kordestan University of Medical Sciences 2004; 8(3): 59-67. [In Persian].
5. Medicare Services Advisory Committee. Positron Emission Tomography. Part 2(ii). Canberra: Medicare Services Advisory Committee; 2001.
6. American Cancer Society.Lung Cancer (Non-Small Cell) [Online] 2007. [cited 2007 Oct 31]; Available from: URL: http://www.cancer.org/
7. Cleemput I, Dargent G, Poelmans J, Camberlin C, Van Del Burel A, Ramaekers D. HTA Tomographie par Emission de Positrons en Belgique. KCE Reports; 2005. p. 22
8. Laupacis A. Health Technology Assessment of PET. Toronto: Institute for Clinical Evaluative Sciences (ICES); 2001.
9. Danish Centre for Evaluation and Health Technology Assessment. Positron Emission Tomography (PET) with 18-F-Fluorodeoxyglucose (FDG). A Literature Review of Evidence for Clinical use in the Fields of Oncology, Cardiology and Neurology. Copenhagen: DACEHTA; 2001.
10. Bourguet P, Bosquet L, Corone C, Devillers A, Foehrenbach H, Lumbroso JD, et al. Recommendations for clinical practice: Standards, Options and Recommendations for utilization of positron emission tomography with [18F]-FDG (FDG-PET) in oncology (full report). Paris: FNCLCC,Recommendations for clinical practice. [Online] 2003. Available from URL: http://www.fnclcc.fr/, 2003.
11. HTBS-HTA (Health Technology Board for Scotland). Positron Emission Tomography (PET) Imaging in Cancer Management. Glasgow: Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS); 2002.
12. AETMIS. Positron emission tomography in Quebec. Montreal [Online] 2003. Available from URL: http://www.aetmis.gouv.qc.ca, 2003.
13. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45(1): 85-92.
14. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14(1): 123-30.
15. Dobert N, Menzel C, Berner U, Hamscho N, Wordehoff N, Mitrou P, et al. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm 2003; 18(4): 565-71.
16. Itti E, Haioun C, Rahmouni A, Reyes F, Meignan M. Agressive large cell lymphoma: early assessment of therapeutic efficacy by positron emission tomography. Medecine Nucleaire 2004; 28(7): 327-32.
17. Zinzani PL, Chierichetti F, Zompatori M, Tani M, Stefoni V, Garraffa G, et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 2002; 43(6): 1239-43.
18. Hicks RJ, Binns DS, Fawcett ME, Ware RE, Kalff V, McKenzie AF, et al. Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. Med J Aust 1999; 171(10): 529-32.
19. NHS Quality Improvement Scotland. HTA Report 2: Positron emission tomography (PET) imaging in cancer management; Understanding HTBS Advice; Use of PET imaging for cancer in Scotland. Amendment to full report published July 2005. Glasgow: National Institue for Health Research; 2005.